Johnson & Johnson’s closely watched experimental COVID-19 vaccine prevented 66 percent of moderate and severe global cases in a large late-stage study, the company said Friday.
The vaccine, which uses technology pioneered by the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, prevented 72 percent of US cases in the clinical trial, which involved about 45,000 volunteers across the world.
Read the full story on BostonGlobe.com.
|
|
|
|
|
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
|
|
|
|
